H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Karuna Therapeutics to $300 from $320 and keeps a Buy rating on the shares. The analyst expects Karuna to file for approval of KarXT in mid-2023, with possible approval in the second half of 2024. It cites equity dilution for the target drop.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRTX:
- Royalty Pharma acquires interest in PureTech’s royalty in Karuna’s KarXT
- Biotech Alert: Searches spiking for these stocks today
- Karuna Therapeutics 2.48M share Secondary priced at $161.33
- Karuna Therapeutics announces $400M offering of common stock
- Karuna Therapeutics Down Even after Positive Topline Results
